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Background: Metabotropic glutamate 7 (mGlu7) receptor is a crucial target protein for the development of
pharmaceuticals against central nervous system disorders. In the present study, we synthesized [11C]MMPIP, a
putative radioligand for mGlu7 (binding constant KB = 30 nM), and evaluated its potential for imaging of mGlu7 via
in vitro and in vivo techniques.
Methods: [11C]MMPIP was synthesized by the reaction of phenol precursor 3 with [11C]CH3I. In vitro
autoradiography using [11C]MMPIP was performed on rat brain sections. To determine in vitro specific binding of
[11C]MMPIP with mGlu7, a blocking study was conducted by co-incubation with excess AMN082, a selective
antagonist for mGlu7, or unlabeled MMPIP. Positron emission tomography (PET) studies and ex vivo metabolite
analysis were carried out on rat brains.
Results: [11C]MMPIP was obtained with two specific activity (SA) levels of average 58 (conventional) and 3,800 (high
SA) GBq/μmol, respectively. High radioactive signals derived from conventional [11C]MMPIP in the in vitro
autoradiography were seen in the thalamus, medulla oblongata, and striatum, corresponding with comprehensive
brain distributions of mGlu7. Co-incubation with ANM082 or unlabeled MMPIP reduced the radioactive signals in
the brain sections, respectively. In the PET studies with [11C]MMPIP, no specific uptake relative to mGlu7 was found
in the examined brain regions.
Conclusion: Despite in vitro specific binding of [11C]MMPIP with mGlu7, visualization of mGlu7 in the living brain
using PET was not successful. Development of new ligand candidates with higher affinity for mGlu7 is necessary.
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Glutamate is a dominant neurotransmitter in the mam-
malian central nervous system (CNS), inducing excita-
tory neurotransmission by binding to its receptors.
Glutamate receptors are classified as metabotropic or
iontropic types based on their biological functions and
molecular structures [1,2]. Eight subtypes of metabotro-
pic glutamate receptors (mGlu1 to 8) have been identi-
fied and divided into three groups based on sequence
homology, pharmacology, and coupling pathway to G* Correspondence: zhang@nirs.go.jp
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in any medium, provided the original work is pproteins [3]. So far, major drug discovery programs have
largely focused on group I (mGlu1 and mGlu5) and II
(mGlu2 and mGlu3), which have been implicated in
various neuropathological and psychiatric disorders
[4-6]. On the other hand, the group III receptors includ-
ing four subtypes, such as mGlu4 and mGlu6 to 8, are
less understood, mainly due to the paucity of specific li-
gands for these receptors.
Of the group III receptors, mGlu7 is mainly localized
on the presynaptic terminals of glutamatergic neurons,
and its signaling pathways are activated only under con-
ditions of emergency synaptic activity because of its low
affinity to glutamate [7]. Studies on mGlu7-deficient
mice have directly demonstrated that mGlu7 plays theis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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via feedback regulation of glutamate in the synaptic
cleft [8]. Moreover, mGlu7 is known to regulate glu-
tamate release through modulation of cAMP levels in
cerebrocortical nerve terminals [9]. Recent advances in
the generation of transgenic animals and the identifica-
tion of selective or specific ligands have revealed im-
portant insights into the potential role of mGlu7 in the
pathophysiology of neurological disorders [10,11].
MMPIP (6-(4-methoxyphenyl-5-methyl-3-pyridin-4-
ylisozazolo[4,5-c]pyridine-4(5H)-one, Figure 1) has been
previously developed as an allosteric antagonist for
mGlu7 [11]. MMPIP intercepts agonist-induced Gq-
coupled Ca2+ mobilization and the Gi-coupled cAMP
pathway and is used as a promising pharmacological
tool for elucidating the role of mGlu7 in CNS functions
[12,13]. The binding constant (KB) value of MMPIP
against binding of L-(+)-2-amino-4-phosphonobutyric
acid (L-AP4), an agonist for mGlu7-induced Ca2+
mobilization, with mGlu7 was 30 nM. In addition, IC50
values of MMPIP against L-AP4-induced cAMP accu-
mulation in Chinese hamster ovary (CHO)-rat mGlu7
and CHO-human mGlu7 cells were 220 ± 23 nM and
610 ± 130 nM, respectively [12].
Positron emission tomography (PET) is frequently
used as a tool for basic and clinical studies to elucidate
the distribution, function, and downregulation or
upregulation of neuroreceptors in living brains of ani-
mals and human. Although mGlu7 is known to be an






MMPIP: R = CH3
[11C]MMPIP: R = 11CH
Figure 1 Chemical structures.knowledge, there have been no PET ligands developed
for the imaging of mGlu7 until now. In this study, we
aimed to develop 11C-labeled MMPIP ([11C]MMPIP,
Figure 1) and to evaluate its potential as the first puta-
tive radioligand for imaging of mGlu7 in the brain. Here,
we describe the following:
1. Radiosynthesis of [11C]MMPIP with conventional
(average 58 GBq/μmol) and high specific activity
(SA) (average 3,800 GBq/μmol)
2. In vitro autoradiography using rat brain sections
3. PET studies with [11C]MMPIP of two SA levels on
rat brains




The melting point (mp) was measured using a micro-
melting point apparatus (MP-500P, Yanaco, Tokyo,
Japan) and uncorrected. 1H-NMR (300 MHz) spectra
were recorded on a spectrometer (JEOL-AL-300, JEOL,
Tokyo, Japan) with tetramethylsilane as an internal
standard. All chemical shifts (δ) were reported in parts
per million downfield relative to the chemical shift of
tetramethylsilane. High-resolution mass spectra (HRMS)
were obtained on a JEOL NMS-SX102 spectrometer
(JEOL). All chemicals and solvents were of analytic or
high-performance liquid chromatography (HPLC) grade
and were purchased from two commercial suppliers
(Sigma-Aldrich, St. Louis, MO, USA and Wako Pure In-
dustries, Osaka, Japan). Column chromatography was
performed using Wako gel C-200 (70 to 230 mesh). The
authentic MMPIP was prepared according to procedures
reported previously [11,14]. The selective mGlu7 antag-





A solution of lithium bis(trimethysilyl)amide in hexane
(9.6 mL, 1.0 M) was added dropwise to a solution
of N-(5-methyl)-3-(pyridin-4-yl)isoxazole-4-carboxamide
[11,14] (0.87 g, 4.0 mmol) in anhydrous tetrahydrofuran
(THF, 20 mL) under N2 gas at −40°C. The reaction mix-
ture was continuously stirred at −40°C for 30 min. A so-
lution of methyl 4-tert-butyl-dimethylsilyloxybenzoate
(2.66 g, 10 mmol) in anhydrous THF (20 mL) was added
dropwise to the mixture at −40°C. The reaction mixture
was stirred at room temperature overnight. The mixture
was treated with a saturated NH4Cl solution and
extracted with ethyl acetate. After the organic layer was
washed with a saturated NaCl solution, dried with
Yamasaki et al. EJNMMI Research 2013, 3:54 Page 3 of 10
http://www.ejnmmires.com/content/3/1/54MgSO4, and evaporated under reduced pressure, the
crude product was purified by column chromatography
with CH2Cl2/CH3OH (99:1) to give 1 (1.31 g, 72.6%) as
an amorphous compound. 1H-NMR (CDCl3, δ): 8.74
(2H, dd, J = 2.1, 4.6 Hz), 8.02 (2H, d, J = 8.8 Hz), 7.71
(2H, dd, J = 2.1, 4.4 Hz), 7.17 (1H, br), 6.96 (2H, dd, J =
2.9, 6.8 Hz), 4.62 (2H, s), 2.92 (3H, d, J = 12.1 Hz), 1.00




To a solution of 1 (1.26 g, 2.8 mmol) in anhydrous THF
(5 mL), a solution of tetrabutylammonium fluoride in
THF (5 mL, 1.0 M) was added. This reaction mixture
was stirred at room temperature overnight. The mixture
was treated with water and extracted with ethyl acetate.
After the organic layer was washed with a saturated
NaCl solution, dried with MgSO4, and evaporated under
reduced pressure, the crude product was purified by
column chromatography with CH2Cl2/MeOH (99:1) to
give 2 (0.59 g, 62.0%) as a colorless solid; mp: 194°C
to 196°C. 1H-NMR (DMSO-d6, δ): 10.55 (1H, s), 8.73
(2H, dd, J = 1.5, 4.8 Hz), 8.22 (1H, d, J = 4.8 Hz),
7.93 (2H, d, J = 8.8 Hz), 7.65 (2H, dd, J = 1.5, 4.8 Hz),
6.91 (2H, d, J = 8.4 Hz), 4.80 (2H, s), 2.66 (3H, d, J = 4.4




p-Toluenesulfonic acid monohydrate (310 mg, 1.6
mmol) was added to a suspension of 2 (550 mg, 1.6
mmol) in 1,4-dioxane (60 mL). The reaction mixture
was heated at reflux for 12 h. This mixture was treated
with a saturated Na2CO3 solution and extracted with
ethyl acetate. The organic layer was washed with a satu-
rated NaCl solution, dried with MgSO4, and evaporated
under reduced pressure. The crude product was then
purified by column chromatography with CH2Cl2 in
CH3OH (1% to 5%) to give 3 (20.0 mg, 3.8%; overall
yield: 1.7% from 1) as a colorless solid; mp: 189°C. 1H-
NMR (DMSO-d6, δ): 10.00 (1H, s), 8.80 (2H, dd, J = 1.6,
4.6 Hz), 8.24 (2H, dd, J = 1.7, 4.6 Hz), 7.39 (2H, d, J =
8.4 Hz), 6.92 (2H, d, J = 8.8 Hz), 6.83 (2H, s),




[11C]CH3I was synthesized from cyclotron-produced
[11C]CO2 as described previously [15]. Briefly, [
11C]CO2
was bubbled into 50 μM LiAlH4 in anhydrous THF (0.5
mL). After evaporation of THF, the remaining complexeswere treated with 57% HI (0.3 mL) to produce [11C]
CH3I, which was transferred under N2 gas with heating
into a reaction vessel containing anhydrous DMF (0.3
mL), 3 (1.0 mg), and NaOH (0.01 mL, 0.5 M) cooled
to −15°C to −20°C. After the radioactivity reached a plat-
eau, the reaction vessel was warmed to 80°C. After 3
min of reaction at 80°C, CH3CN/H2O (55:45, 0.5 mL)
was added to terminate the reaction. The radioactive
mixture was applied to a semi-preparative HPLC system.
HPLC purification was completed on a Capcell Pak UG-
80 C18 column (10 mm ID × 250 mm; Shiseido, Tokyo,
Japan) using a mobile phase of CH3CN/H2O (55:45) at a
flow rate of 5.0 mL/min. The retention time (tR) for
[11C]MMPIP was 9.5 min, whereas for 3, 6.7 min. The
radioactive fraction corresponding to [11C]MMPIP was
collected in a sterile flask containing polysorbate 80 (75
μL) and ethanol (150 μL), evaporated to dryness under
vacuum, re-dissolved in sterile normal saline (3.0 mL),
and passed through a 0.22-μm Millipore filter (Billerica,
MA, USA) for analysis and animal experiments.
The radiochemical purity of [11C]MMPIP was assayed
by analytical HPLC (Capcell Pak UG-80 C18, 4.6 mm
ID × 250 mm; CH3CN/H2O = 55:45, 1.0 mL/min)
coupled with a UV detector (UV-2075 plus, JASCO,
Tokyo, Japan). The identity of [11C]MMPIP was con-
firmed by co-injection with the unlabeled MMPIP. The
SA of [11C]MMPIP was calculated by a comparison of
the assayed radioactivity to the carrier mass which was
measured from its UV peak at 254 nm.
To determine the stability of [11C]MMPIP with con-
ventional SA, after this product was maintained for 120
min at room temperature, analytic sample was taken
from the formulated solution of [11C]MMPIP to meas-
ure the radiochemical purity in the solution.
High SA
[11C]CH3I for radiosynthesis was synthesized by the
single-pass I2 method as described previously [16]. The
cyclotron-produced [11C]CH4 was passed through a
heated I2 column and converted to [
11C]CH3I, which
was then reacted with 3 (1.0 mg) in the presence of
NaOH (10 μL, 0.5 M). After the reaction, the radioactive
mixture was treated as described for the conventional
SA.
The product was analyzed to measure SA and confirm
the identity by radio-HPLC (Waters XBridge Shield
RP18, 2.5 μm, 3.0 × 50 mm) coupled with a UV detector
(Waters 2487, 210 nm). The mobile phase was a mixture
of CH3CN and 100 mM ammonium phosphate buffer
(pH 2.0) containing 5 mM sodium 1-octanesulfonate
with a ratio of 40:60 under a flow rate of 1.0 mL/min. A
solution of unlabeled MMPIP at a concentration of
19.35, 25.8, 64.5, 129, and 258 pmol/mL was prepared
from a standard solution (2.58 μmol/mL CH3CN). A
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tions three times at each measurement. The high SA
product was loaded into a sample loop (5 μL) and
injected into the HPLC. The SA value was decay-
corrected to the time when the radioactivity of product
was measured at the end of synthesis (EOS). The detec-
tion limit of this technique was 15.3 pmol/mL under this
analytic condition.
To determine the stability of [11C]MMPIP with high
SA, after this product was maintained for 120 min at
room temperature, analytic sample was taken from the
formulated solution of [11C]MMPIP to measure the
radiochemical purity in the solution.
Measurement and computation of partition coefficient
Partition coefficient (Log D) values were measured by
mixing conventional SA [11C]MMPIP (radiochemical
purity 99.3%, about 160,000 cpm) with n-octanol (3.0 g)
and sodium phosphate buffer saline (PBS, 3.0 g; 0.1 M,
pH 7.40) in a test tube. The tube was vortexed for 3 min
at room temperature, followed by centrifugation with
AT-2724 rotor (KUBOTA, Tokyo, Japan) at 3,500 rpm
for 5 min. An aliquot of 1 mL PBS and 1 mL n-octanol
was removed, weighted, and counted, respectively. Sam-
ples from the remaining organic layer were removed and
re-partitioned until consistent Log D value was obtained.
The Log D value was calculated by comparing the ratio
of counts per minute per gram of n-octanol to that of
PBS and expressed as Log D = Log[cpm/g (n-octanol)/
cpm/g (PBS)]. All assays were performed in triplicate.
Meanwhile, the value of cLog D of [11C]MMPIP was
computed using Pallas 3.4 software (CompuDrug,
Sedona, AZ, USA).
Animals
Sprague–Dawley (SD) rats were purchased from Japan
SLC (Shizuoka, Japan). The animal experimental proce-
dures were approved by the Animal Ethics Committee
of the National Institute of Radiological Sciences (Chiba,
Japan).
In vitro autoradiography
Sagittal sections (8 μm) were prepared from a frozen rat
brain using a cryostat (HM560, Carl Zeiss, Oberkochen,
Germany). Brain sections were pre-incubated in a 50
mM Trizma buffer containing 1.2 mM MgCl2 and 2.0
mM CaCl2 at room temperature for 20 min. After [
11C]
MMPIP (74 MBq, 0.7 nmol) was added to the incuba-
tion buffer (0.2 L), the brain sections were incubated in
the buffer for 60 min at room temperature. To deter-
mine the specific binding of [11C]MMPIP for mGlu7, we
added AMN082, a selective antagonist for mGlu7 [17],
or unlabeled MMPIP (10 μM, dissolved in saline
containing 20% ethanol and 10% polysorbate 80) to eachincubation buffer in advance, respectively. After incuba-
tion, these sections were washed three times for 5 min
each time with cold buffer, dipped in cold distilled water,
and dried with cold air. These sections were placed in
contact with an imaging plate (BAS-MS2025, Fujifilm,
Tokyo, Japan). Autoradiograms were acquired using a
Bio-Imaging Analyzer System (BAS5000, Fujifilm,
Tokyo, Japan). The regions of interest (ROIs) were
manually drawn on the cerebral cortex, striatum, hippo-
campus, thalamus, cerebellum, middle peduncle, and
medulla oblongata. The radioactivity in the ROIs was
quantified and expressed as photo-stimulated lumines-
cence per unit area (PSL/mm2).
Small-animal PET
A male SD rat (n = 3, 280 to 385 g; 7 to 10 weeks old)
was secured in a custom-designed chamber and placed
in a small-animal PET scanner (Inveon, Siemens Medical
Solutions, Knoxville, TN, USA). A 24-gauge intravenous
catheter (Terumo Medical Products, Somerset, NJ, USA)
was placed in the tail vein for a bolus injection. The
rat was kept under anesthesia with 1.5% (v/v) isoflurane
during the scan, and its body temperature was maintained
with a 40°C water circulation system (T/Pump TP401,
Gaymar Industries, Orchard Park, NY, USA).
The dynamic emission scans in 3D list mode were
performed for 60 min (1 min × 4 frames, 2 min × 8 frames,
and 5 min × 8 frames) on a rat brain after intravenous in-
jection of [11C]MMPIP with a radioactivity of 51 ± 5 MBq
in 0.2 mL saline. PET dynamic images were reconstructed
by filtered back projection using Hanning’s filter with a
Nyquist cutoff of 0.5 cycle/pixel. Reconstructed PET images
were summed using analysis software (ASIPro VM™,
Analysis Tools and System Setup/Diagnostics Tool, Sie-
mens Medical Solutions, Knoxville, TN, USA). Volumes of
interest were drawn on the striatum, thalamus, pons/me-
dulla, and cerebellum referring to rat brain magnetic reson-
ance imaging template, and the time-activity curves (TACs)
in each region were characterized. Brain uptake of radio-
activity was decay-corrected to the injection time and was
expressed as the standardized uptake value (SUV), which
was normalized to the injected radioactivity and body
weight. SUV was calculated according to the following for-
mula: SUV = (radioactivity per milliliter tissue / injected
radioactivity) × gram body weight.
For the blocking study, a SD rat (n = 3, male, 260 to
280 g; 8 weeks old) was injected with unlabeled MMPIP
(1 mg/kg) 30 s prior to the injection of [11C]MMPIP
(51 ± 5 MBq, 0.5 nmol). The PET procedure and data
analysis were performed as described above.
Metabolite analysis in rat plasma and brain
[11C]MMPIP (37 to 111 MBq, 0.3 to 1.0 nmol in 0.1 to
0.3 mL saline) was injected into SD rats (male, 240 to
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that were anesthetized with 5% (v/v) isoflurane were
sacrificed by cervical dislocation at 5, 15, 30, and 60 min
following a bolus injection. Blood (0.5 to 1.0 mL) and
whole brain samples were quickly removed after sacri-
fice. The blood samples were centrifuged with AT-2724
M rotor (KUBOTA, Tokyo, Japan) at 15,000 rpm for 2
min at 4°C to separate the plasma, 0.25 mL of which
was added to a test tube containing CH3CN (0.5 mL).
The tube was then vortexed for 15 s and centrifuged using
the Minispin plus (Eppendorf, Hamburg, Germany) at
14,500 rpm for 2 min for deproteinization, and the super-
natant was collected. The brain samples were homogenized
together in ice-cooled CH3CN/H2O (1:1, 1.0 mL) solution
using the Silent Crusher S (Heidolph Instruments,
Schwabach, Germany). The homogenate was centrifuged
for 2 min at 4°C and 0.5 mL of the supernatant was added
to a test tube containing CH3CN (0.5 mL). The tube was
then vortexed for 15 s and centrifuged for 2 min for
deproteinization, and the supernatant was collected. An ali-
quot of the supernatant (0.1 to 0.3 mL) prepared from the
plasma or brain homogenate was analyzed by HPLC with a
highly sensitive detector for radioactivity [18] using a
Capcell Pak UG-80 C18 column (4.6 mm ID × 250 mm)
and CH3CN/H2O (1:1) at 1.5 mL/min. The percentage of
unchanged [11C]MMPIP to total radioactivity (corrected for
decay) on the HPLC charts was calculated as the percent-
age of the parent fraction = (peak area for [11C]MMPIP /
total peak areas) × 100.
TACs of intact [11C]MMPIP in the brain were gener-
ated from TACs of total radioactivity corrected by me-
tabolite fraction with three exponential fitting using
PMOD software (version 3.2, PMOD Technologies,
Zurich, Switzerland). TACs of metabolites were obtained

































Figure 2 Chemical synthesis and radiosynthesis. (a) Lithium bis(trimeth
overnight. (b) Bu4NF, THF, room temperature, overnight. (c) p-Toluenesulfon
80°C, 3 min.Results
Chemistry
The phenol precursor 3 for radiosynthesis was synthe-
sized according to the reaction sequences as shown in
Figure 2. Reaction of methoxyisoxazole with lithium
bis(trimethysilyl)amide, followed by treatment with
4-substituted benzoate, gave 5-(2-phenyl-2-oxoethyl)
isoxazole 1. After cleavage of the protecting group in 1,
the obtained 2 was treated with p-toluenesulfonic acid
to give precursor 3.
[11C]MMPIP with two different SA levels was synthe-
sized by O-[11C]methylation of precursor 3 with [11C]
CH3I in DMF at 80°C for 3 min (Figure 2). As for the
conventional SA, [11C]CH3I was produced by reduction
of the cyclotron-produced [11C]CO2 with lithium
aluminum hydride, followed by treatment with HI.
HPLC separation for the reaction mixture gave [11C]
MMPIP with 590 ± 80 MBq (n = 5) as an injectable so-
lution of sterile normal saline at the EOS, starting from
[11C]CO2 of 19 ± 4 GBq, which was produced by 12- to
15-min proton (14.2 MeV on target) bombardment
using a beam current of 15 μA. The decay-corrected
radiochemical yield and synthesis time was 7.3% ± 1.2%
and 25 min from the end of bombardment (EOB). At
EOS, the radiochemical purity and SA was 98.3% ± 0.4%
and 58 ± 25 GBq/μmol (n = 5). The radiochemical pur-
ity of [11C]MMPIP remained at 96.0% ± 0.7% (n = 3)
after maintaining this product at room temperature over
120 min.
As for the high SA, [11C]CH3I was produced by iodin-
ation of the cyclotron-produced [11C]CH4. At EOS,
800 ± 170 MBq (n = 5) of [11C]MMPIP was obtained
starting from 39 ± 2 GBq of [11C]CH4, which was pro-
duced by 30-min proton bombardment using a beam





















ysilyl)amide in hexane, THF, −40°C, 30 min then room temperature,
ic acid monohydrate, 1,4-dioxane, reflux, 12 h. (d) DMF, NaOH,
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from EOB. At EOS, the radiochemical purity and SA
was 97.8% ± 0.6% and 3,800 ± 625 GBq/μmol (n = 5).
[11C]MMPIP of high SA also showed stability (>95.0%
radiochemical purity, n = 3) for radiolysis after
maintaining this product over 120 min.
Measurement of Log D and computation of cLog D
The measured Log D value of [11C]MMPIP was 3.17 ±
0.02 (n = 3). The computed value of cLog D for MMPIP
was 2.95.
In vitro autoradiography
Figure 3A,B,C shows representative in vitro autoradio-
grams using [11C]MMPIP co-incubated with vehicle, 10
μM of AMN082, or 10 μM of unlabeled MMPIP, re-
spectively. In the control section, strong radioactive
signals were observed in the thalamus and medulla
oblongata, followed by the striatum, middle peduncle,
and cerebral cortex (Figure 3A). By co-incubation with
excess AMN082 (Figure 3B) or unlabeled MMPIP
(Figure 3C), the radioactive signals in the brain section
were homogeneously decreased, compared to the signals
in the control section. The decrease rate of radioactive
signals in each brain region was 34% to 53% for
AMN082 treatment and 41% to 60% for unlabeled
MMPIP treatment, respectively.
Small-animal PET
Figure 4A shows a representative PET image of the rat
brain for [11C]MMPIP with conventional SA. In the
horizontal PET image, radioactive signals weakly spread
over the whole brain. There were no significant regional
differences of uptake of radioactivity in all over the
brain.
Figure 4B,C shows the TACs of [11C]MMPIP with con-
ventional SA in the brain regions in the baseline and
blocking study with excess MMPIP. All curves in each
brain region showed high initial uptake but rapid clear-
ance. No significant difference between baseline and
blockade was observed.
Figure 4D shows the TACs of [11C]MMPIP with high






Figure 3 In vitro autoradiography using rat brain sections. Slides were
AMN082 (B), or 10 μM of unlabeled MMPIP (C). Cb, cerebral cortex; Ce, cer
medulla oblongata; Mi, middle peduncle; Th, thalamus; St, striatum.showed a rapid clearance of radioactivity peaking at the
initial phase following commencement of the PET scan,
which was similar to the kinetics of the conventional
[11C]MMPIP.
Metabolite analysis in rat plasma and brain
Table 1 shows the percentages of unchanged [11C]
MMPIP in the plasma and brain. The fraction corre-
sponding to unchanged [11C]MMPIP (tR = 5.8 min) in
the plasma gradually decreased to 48% at 15 min and
18% at 60 min after the injection. Two major
radiolabeled metabolites (tR = 2.1 and 3.0 min) were
observed on the HPLC charts. On the other hand, un-
changed [11C]MMPIP in the brain homogenate
remained at 72% of total radioactivity at 15 min after
the injection and decreased with time after that. At 60
min, the percentage of intact form in the brain was
close to that in the plasma. Two radiolabeled metabo-
lites in the plasma were also detected in the brain.
Figure 5 shows the TACs of total, intact, and
radiolabeled metabolites in the brains. Total radioactivity
decreased very slowly following a rapid decrease. In con-
trast, the metabolites gradually increased until 60 min
after the injection.
Discussion
Currently, mGlu7 is recognized as a targeted receptor for
the development of pharmaceuticals against CNS disor-
ders, such as epilepsy [19,20], schizophrenia [21-23], and
anxiety [10,24,25]. In fact, studies on mGlu7-deficient
mice directly demonstrated that mGlu7 is involved in the
neurobiological mechanisms underlying the conceptually
diverse phenomena of anxiety, fear extension, and spatial
working memory [10]. Owing to these backgrounds,
development of a PET ligand for mGlu7 has become the
object of our study.
In the present study, we succeeded in the
radiosynthesis of [11C]MMPIP (Figure 1) as a potential
PET ligand for mGlu7, with two SA levels (average
values 58 GBq/μmol and 3,800 GBq/μmol, respect-
ively). To evaluate the utility of [11C]MMPIP for the
imaging of mGlu7, we performed in vitro and in vivo
studies on rat brains.C
incubated with [11C]MMPIP including the vehicle (A), 10 μM of




Figure 4 PET studies with [11C]MMPIP in the rat brain. (A) representative PET images of [11C]MMPIP with conventional SA on the horizontal
slice. (B) time-activity curves (TACs) of [11C]MMPIP with conventional SA (58 GBq/μmol) in the thalamus (open circles), cerebellum (open squares),
cerebral cortex (open triangles), striatum (filled squares), and pons/medulla (filled circles) of baseline rats. (C) TACs of the blocking study with
unlabeled MMPIP (1 mg/kg). (D) TACs of [11C]MMPIP with high SA (3,740 GBq/μmol).
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performed using rat brain sections. It has been reported
that mRNA of mGlu7 was highly expressed in the hypo-
thalamus, thalamus, cerebral cortex, striatum, and mid-
brain of the rat brain [7,26]. However, immunostaining
with mGlu7-directed antibodies has demonstrated that
the distribution of immunoactivity was particularly high
in sensory areas, such as the piriform cortex, superior
colliculus, dorsal cochlear nucleus, and spinal nuclei
[27]. Bradley et al. explained that the difference in re-
gional distribution between the two studies might be
due to synaptic localization of mGlu7 [27]. In our auto-
radiogram of the control (Figure 3A), highly radioactive
accumulations were detected on the thalamus and me-




Intact Metabolite 1 Metabo
5 81.3 ± 8.4 13.4 ± 6.0 5.3 ±
15 48.7 ± 4.1 36.7 ± 5.8 14.6 ±
30 30.6 ± 3.7 43.3 ± 1.2 26.1 ±
60 18.0 ± 0.3 62.1 ± 3.9 19.9 ±
Percentages are expressed as mean ± S.D., n = 3.striatum and middle peduncle, and a low level was seen
on the cerebellum. This pattern showed a comprehen-
sive distribution of mGlu7, as also seen in the two previ-
ous reports. Moreover, by co-incubation with excess
AMN082 or unlabeled MMPIP, specific binding of [11C]
MMPIP with mGlu7 was verified in the brain regions.
This finding motivated us to progress in vivo study.
Contrary to the in vitro result, in vivo specific binding
was not observed in the rat brain using PET with [11C]
MMPIP (Figure 4). To decrease the influence of un-
labeled MMPIP that were mixed in the preparation of
conventional SA on the putative specific binding, we fur-
ther synthesized [11C]MMPIP with high SA. The mass
amount of unlabeled MMPIP in the high SA preparation
was 65-fold less than that in the conventional SA. PET]MMPIP in the plasma and brain
Brain
lite 2 Intact Metabolite 1 Metabolite 2
2.5 92.0 ± 2.7 1.5 ± 0.5 6.5 ± 2.5
2.5 72.3 ± 3.6 8.2 ± 0.7 19.5 ± 3.0
4.9 36.2 ± 2.9 23.1 ± 2.4 40.7 ± 5.2
3.6 18.5 ± 3.5 47.9 ± 12.7 33.5 ± 9.2
Figure 5 Radioactive compositions in the rat brain. TACs
showed total radioactivity (filled circles), intact (open squares),
and two metabolites (open triangles). The TACs in the intact and
metabolites were corrected by a fitting curve obtained from
metabolite fractions of the brain.
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http://www.ejnmmires.com/content/3/1/54ligands with high SA enable to successfully visualize
brain receptors with small changes and to elucidate
slight binding sites [28-30]. However, in the present
study, there was no difference in kinetics and the distri-
bution pattern of uptake between the two SA levels
(Figure 4B,C,D).
The reasons for this failure to visualize in vivo specific
binding of [11C]MMPIP with mGlu7 can be understood
by considering the following factors [31]. The first is the
limiting effect via ATP-binding cassette transporters
[32], such as P-glycoprotein and breast cancer resistant
protein, on the blood–brain barrier (BBB) against the
entrance of [11C]MMPIP into the brain. As shown in the
TACs (Figure 4B), [11C]MMPIP showed an acute initial
uptake into the brain, reaching a maximum SUV of 1.9
at 3 min following the injection. This quick brain pene-
tration of [11C]MMPIP was probably dependent on its li-
pophilicity (Log D = 3.17), which was within the range
generally considered to be suitable as a PET ligand for
brain imaging [31]. This result suggested that trans-
porters did not have a significant limiting effect on the
brain penetration of this radioligand.
The second is the influence of radiolabeled metabolites
of [11C]MMPIP in the brain. If the radiolabeled metabo-
lites penetrate into the brain, signals of specific binding
to a target receptor may be obscured by non-specific
binding signals and hidden by background signal. In the
present study, although unchanged [11C]MMPIP in the
brain was retained at >70% at 15 min after the injection,
the percentage of intact form decreased to a level closeto that in the plasma at 60 min (Table 1). In fact, the
radioactivity level of metabolites increased in the brain
with time after the injection (Figure 5). These results
suggested that the radiolabeled metabolites in the brain
may weaken the putative specific signals of [11C]MMPIP
for mGlu7 to some extent.
The third and perhaps most important factor is the
binding affinity of [11C]MMPIP for mGlu7. The ratio of
the density (Bmax) of target receptors in the brain re-
gions of interest to the equilibrium dissociation constant
(KD) of a radioligand [33] is commonly used to predict
the magnitude of specific binding in a PET study with
the radioligand. In the present positron-emitter
radioligands, the ratio of Bmax/KD, also referred to as
binding potential, should ideally be greater than 2 to
achieve a measurable specific binding on the basis of in-
dividual experiences [34-36]. For example, the KD value
of [11C]raclopride, a PET ligand for dopamine D2
receptor, was roughly 8 nM, and Bmax of D2 receptor in
the striatum was 20 nM; the ratio of Bmax/KD was
about 2.5 [37].
It is known that mGlu receptors in group III are
expressed widely throughout the brain at both mRNA
and protein levels, and they are present at both
glutamatergic and GABAergic terminals [38]. However,
to our knowledge, there has been no report involving
the individual density of mGlu7 to date. The density
(Bmax) of other mGlu receptors has been reported, e.g.,
mGlu1, 82 nM in the cerebellum of rat brain [39];
mGlu5, roughly 120 nM in the rat brain homogenate
[40]. If mGlu7 is expressed at a similar Bmax to mGlu1
or mGlu5 in the rat brain, mGlu7 might be visualized
using [11C]MMPIP, because the functional binding con-
stant (KB) of MMPIP for mGlu7 was reported to be 30
nM [12]. However, the present results give insights such
that the mGlu7 density in the rat brain may be much
lower than the density of mGlu1 or mGlu5. Thus, to
achieve visualization of mGlu7 in the brain with PET,
the development of novel ligand candidates with at least
one order higher binding affinity for this receptor than
MMPIP is required.
Conclusion
In the present study, we succeeded in achieving the
radiosynthesis of [11C]MMPIP with two different SA
levels as the first potential radioligand for mGlu7 and
demonstrated its specific binding using in vitro autoradi-
ography. However, visualization of mGlu7 in the rat
brain using PET was not successful because of the low
affinity of MMPIP for mGlu7. In addition, radiolabeled
metabolites entering the brain might also weaken the
signal of specific binding of [11C]MMPIP to some extent.
In the future, it is necessary to develop new ligand can-
didates which have higher binding affinity to mGlu7 and
Yamasaki et al. EJNMMI Research 2013, 3:54 Page 9 of 10
http://www.ejnmmires.com/content/3/1/54a more suitable profile of metabolism than MMPIP for
the PET imaging of mGlu7 in the brain.
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